ACRV Stock Forecast: Acrivon Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Acrivon Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Acrivon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (28): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ACRV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ACRV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | Citizens | Reiterates | Market Outperform | $13 |
| 9 Jan 2026 | Piper Sandler | Maintains | Overweight | $6.00 → $8.00 |
| 25 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 16 May 2025 | Jones Trading | Downgrade | Hold | — |
| 15 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 26 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 26 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 26 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Jan 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 14 Nov 2024 | BMO Capital | Maintains | Outperform | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright& Co. | Reiterates | Buy | — |
| 16 Sept 2024 | BMO Capital | Reiterates | Outperform | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 16 Sept 2024 | Ladenburg Thalmann | Upgrade | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACRV.
This page is one stock. Monday covers all of them.
ACRV appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ACRV vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Acrivon Therapeutics, Inc. returned −49.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ACRV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −74.1%
- Return on assets
- −41.8%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Acrivon Therapeutics, Inc. has a market value of $49.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$74.2M.
Free cash flow in the twelve months to 30 June 2026: −$64.1M.
Acrivon Therapeutics, Inc. employs 74 people.
Data provided by Twelve Data
ACRV and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ACRV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Acrivon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ACRV
What is the ACRV stock price forecast for 2026-2027?
The median 12-month analyst price target for Acrivon Therapeutics, Inc. is $11, with estimates ranging from $7 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACRV stock a buy right now?
Of the 7 analysts covering Acrivon Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acrivon Therapeutics, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACRV?
As at 21 Nov 2026, Acrivon Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).
Will ACRV stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $11, and Ticker Nerd's factor model ranks Acrivon Therapeutics, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACRV stock forecast for 2030?
No analyst covering Acrivon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $19 over the next 12 months.
How has ACRV stock performed over the past year?
Acrivon Therapeutics, Inc. returned -49.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Acrivon Therapeutics, Inc. do?
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.
CEO Dr. Peter Blume-Jensen M.D., Ph.D. · 74 employees · United States · https://acrivon.com